Koyama et al., demonstrated that TIM-3 upregulation following PD-1 blockade was a mechanism of acquired resistance to nivolumab in non-small cell lung cancer patients [26]. The gene discussed is HAVCR2; the disease is non-small cell lung carcinoma.